Meziani Jihane, Sprij Marloes L J A, Fuhler Gwenny M, Bruno Marco J, Marchegiani Giovanni, Cahen Djuna L
Department of Gastroenterology & Hepatology, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Department of Public Health, University Medical Center Rotterdam, Rotterdam, The Netherlands.
United European Gastroenterol J. 2025 Feb;13(1):7-20. doi: 10.1002/ueg2.12666. Epub 2024 Oct 6.
For branch-duct intraductal papillary mucinous neoplasms (BD-IPMNs) without worrisome features (WFs) or high-risk stigmata (HRS), current guidelines recommend surveillance. However, these intraductal papillary mucinous neoplasm (IPMNs), especially the small and stable-sized ones, carry a low risk of malignant transformation. Our aim was to assess whether small cyst size and absence of rapid growth provide reassurance against the development of WFs/HRS and malignancy (high-grade dysplasia (HGD) or pancreatic cancer (PC)).
PubMed/Medline, Embase, the Cochrane Library and the Web of Science Core Collection were systematically searched from inception to May 2023 to identify studies investigating surveillance outcomes of low-risk BD-IPMNs. Studies assessing baseline cyst size and/or growth in relation to WFs/HRS and/or HGD/PC were included. The Newcastle-Ottawa scale tool was used to assess study quality.
Of the 1937 identified manuscripts, 21 studies were eligible for inclusion. The quality of these studies was considered reasonable. A negative association between cyst size and WFs/HRS development was found in 11 out of 13 relevant studies, but only one out of nine studies reported a negative association between size and malignancy. Regarding cyst growth, four out of six studies described a negative association with the development of WFs/HRS, and all six reported a negative association with malignancy. The pooled relative risk (RR) of developing WFs/HRS or malignancy for cysts ≤15 mm was 0.37 (95% CI 0.25-0.57) and the RR of developing malignancy for cyst growth <2-2.5 mm/year was 0.04 (95% CI 0.02-0.09)).
This systematic review and meta-analysis shows that small and stable-sized low-risk BD-IPMNs are associated with a markedly low progression rate, with stable cyst size being the most reassuring feature. Because of substantial heterogeneity in definitions and reported outcome measures, prospective studies are needed to confirm that surveillance of small and stable sized cyst can be de-intensified or even discontinued.
对于无可疑特征(WFs)或高危征象(HRS)的分支导管内乳头状黏液性肿瘤(BD-IPMNs),当前指南推荐进行监测。然而,这些导管内乳头状黏液性肿瘤(IPMNs),尤其是体积小且大小稳定的肿瘤,发生恶性转化的风险较低。我们的目的是评估囊肿体积小且无快速生长是否可确保不会出现WFs/HRS以及恶性肿瘤(高级别异型增生(HGD)或胰腺癌(PC))。
对PubMed/Medline、Embase、Cochrane图书馆和科学引文索引核心合集进行系统检索,检索时间从数据库创建至2023年5月,以确定调查低风险BD-IPMNs监测结果的研究。纳入评估基线囊肿大小和/或生长与WFs/HRS和/或HGD/PC关系的研究。使用纽卡斯尔-渥太华量表工具评估研究质量。
在1937篇检索到的手稿中,21项研究符合纳入标准。这些研究的质量被认为合理。在13项相关研究中的11项中发现囊肿大小与WFs/HRS发生之间存在负相关,但在9项研究中只有1项报告大小与恶性肿瘤之间存在负相关。关于囊肿生长,6项研究中的4项描述了与WFs/HRS发生之间存在负相关,所有6项研究均报告与恶性肿瘤存在负相关。囊肿≤15 mm发生WFs/HRS或恶性肿瘤的合并相对风险(RR)为0.37(95%CI 0.25-0.57),囊肿生长<2-2.5 mm/年发生恶性肿瘤的RR为0.04(95%CI 0.02-0.09)。
本系统评价和荟萃分析表明,体积小且大小稳定的低风险BD-IPMNs进展率明显较低,囊肿大小稳定是最令人安心的特征。由于定义和报告的结局指标存在很大异质性,需要进行前瞻性研究以确认对体积小且大小稳定的囊肿的监测可以减弱甚至停止。